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Background: Inﬂammatory bowel diseases (IBD) are characterized by chronic relapsing inﬂammation of the gastrointestinal tract and encompass Crohn’s
disease and ulcerative colitis. IBD are often associated with extraintestinal manifestations affecting multiple organs including the liver. Increased levels of
serum aminotransferases, possibly related to nonalcoholic fatty liver disease, constitute one of the most frequently described IBD-related liver diseases. The
PNPLA3 I148M substitution is a major common genetic determinant of hepatic fat content and progression to chronic liver disease. The aim of this study was
to investigate whether carriers of PNPLA3 148M allele with IBD have higher risk of liver steatosis and increase in transaminases levels.
Methods: The PNPLA3 I148M (rs738409) genotype was performed by Taqman assays in 158 individuals from Southern Italy (namely, Catanzaro
cohort) and in 207 individuals from Northern Italy (namely, Milan cohort) with a deﬁnite diagnosis of IBD. Demographic and clinical data and also
alanine transaminase levels were collected for both cohorts. The Catanzaro cohort underwent liver evaluation by sonography and liver stiffness and
controlled attenuation parameter measurements by transient elastography.
Results: Here, we show for the ﬁrst time that carriers of the PNPLA3 148M allele with IBD have a greater risk of hepatic steatosis (odds ratio, 2.9, and
conﬁdence interval, 1.1–7.8), higher controlled attenuation parameter values (P ¼ 0.029), and increased circulating alanine transaminase (P ¼ 0.035) in
the Catanzaro cohort. We further conﬁrm the higher alanine transaminase levels in the Milan cohort (P , 0.001).
Conclusions: Our results show that PNPLA3 148M carriers with IBD have higher susceptibility to hepatic steatosis and liver damage.
(Inﬂamm Bowel Dis 2016;22:134–140)
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I nﬂammatory bowel diseases (IBD) are immune-mediated disor-ders characterized by remittent and relapsing progressive inﬂam-
mation of the gastrointestinal tract. There are 2 major clinical forms
of IBD: Crohn’s disease (CD) and ulcerative colitis (UC).1 IBD
are often associated with extraintestinal manifestations involving
various organs. Extraintestinal manifestations of the skin, eyes,
and peripheral joints usually follow the disease activity, whereas
extraintestinal manifestations involving the hepatobiliary and
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pulmonary systems typically do not parallel the disease activity.2–4
Increased circulating levels of aminotransferases represent one of
the most frequently described IBD-related liver diseases; this is
usually ascribed to nonalcoholic fatty liver disease.4 Indeed, the
prevalence of hepatic steatosis ranges from 13% to 100% in indi-
viduals with IBD5 and with no differences between CD and UC.5,6
Several possible mechanisms underlying IBD-related hepatic dam-
age have been already described, including malnutrition, protein
loss, and medications.5 Despite a large number of studies on liver
abnormalities, the pathogenesis of hepatic steatosis and liver dam-
age in individuals with IBD is not completely understood, and it is
not known whether IBD per se represent an independent risk factor
for this condition.
The patatin-like phospholipase domain-containing 3 (PNPLA3)
protein is a triglyceride and retinyl esterase lipase7–9 highly expressed
in human hepatocytes and hepatic stellate cells. The PNPLA3
rs738409 genetic variant is a guanine to cytosine substitution at posi-
tion 617 of the gene, and it encodes an isoleucine to methionine sub-
stitution at position 148 (I148M) of the PNPLA3 protein. This
substitution results in a loss of function of the protein enzymatic
activity.10–13 The PNPLA3 I148M substitution is a major common
genetic determinant of hepatic fat content13 and progression to chronic
liver disease under a large variety of harmful stimuli for the liver
including severe obesity,14 visceral adiposity,15 diet,16,17 viruses,11,18
iron overload,19 and excess alcohol consumption.20 However, it is
not yet known whether PNPLA3 148M carriers with IBD are more
susceptible to chronic liver disease.
The aim of this study was to investigate whether carriers of
PNPLA3 148M allele with IBD have higher risk of liver steatosis
and increase in transaminases levels. Here, we show for the ﬁrst
time that carriers of the PNPLA3 148M allele with IBD have
a greater risk of hepatic steatosis and increased circulating alanine
transaminase (ALT) in a cohort of 158 patients from Southern
Italy. We further conﬁrm the higher ALT levels in an independent
cohort of 207 individuals with IBD from Northern Italy.
MATERIALS AND METHODS
Study Cohorts
Study Cohort Recruitment
A total of 158 consecutive outpatients from the Gastroen-
terology Unit (University Hospital Magna Græcia of Catanzaro)
were recruited between June 2014 and October 2014, namely,
Catanzaro cohort. Patients of both sexes, aged more than 18 years
with a diagnosis of IBD based on established clinical, endoscopic,
radiological, and histological criteria were included in the study.
Demographic and clinical data and also ALT levels were collected
at the time of enrollment. Body mass index (BMI) was calculated
on self-reported height and weight. The data collected include pre-
vious ileocecal resection for CD. Based on Mayo score, 2 (UC)21
and Harvey Bradshaw index, 5 (CD),22 patients have been clas-
siﬁed as having active or inactive (remission) disease.
A total of 207 consecutive outpatients of the Gastroenter-
ology clinic at the “Ospedale Policlinico Milano” were recruited
between 2004 and 2005, namely, Milan cohort. Patients of both
sexes, aged more than 18 years with a deﬁnite diagnosis of IBD
were included in the study. ALT levels were measured on frozen
serum samples. Disease activity and localization have been deter-
mined as described above.
No individuals with at risk alcohol intake (.30/20 g/d in
M/F) were included in the study cohorts.
Liver Evaluation
Sonography
In the Catanzaro cohort, a total of 109 out of 158 patients
underwent sonographic liver evaluation. Abdominal sonography
was performed from the same experience operator with a gray-
scale scanner devices (Toshiba Nemio, Shimoishigami, Japan)
using a 3.5-MHz convex transducer. Individuals were at least 4
hours fasting before the procedure. Before the procedure,
individuals followed a ﬁber free diet and took 80 mg simethicone
three times per day for 3 days. Hepatic steatosis was graded as
mild (steatosis grade 1 or S1), moderate (steatosis grade 2 or S2),
or severe (steatosis grade 3 or S3).
The features of the mild liver steatosis (S1) were deﬁned as
a slight increase in liver echogenicity with a slight exaggeration of
liver and kidney echo discrepancy. Moderate liver steatosis (S2)
features were deﬁned as increase in liver echogenicity and loss of
echoes from the wall of the portal vein with a greater posterior beam
attenuation and greater discrepancy between hepatic and renal echoes.
The features of severe liver steatosis (S3) were deﬁned as a greater
reduction in beam penetration, loss of echoes from most of the portal
vein wall, and an even larger discrepancy between hepatic and renal
echoes.23,24 Hepatic steatosis was deﬁned as a steatosis grade $S1.
Transient Elastography
In the Catanzaro cohort, a total of 109 out of 158 patients
underwent liver stiffness and controlled attenuation parameter
(CAP) measurements by transient elastography using FibroScan
502 touch (Echosens, Paris, France). All measurements were
performed using the 3.5 MHz standard M probe. Transient
elastographic liver evaluation was performed the same day of
sonography from the same operator (which was different from the
one performing the sonography). Measurements were performed
according to manufacture’s instructions.25 Brieﬂy, patient was lying
in the dorsal decubitus position with the right arm in maximal
abduction; the tip of the transducer probe was covered with cou-
pling gel and placed on the skin between the ribs at level of the
right lobe of the liver. Only results from subjects with 10 valid
shots and interquartile range/median liver stiffness ratio #30%
were included in the study according to manufacturer26 (n ¼
106). The ﬁnal liver stiffness result was expressed in kPa and
was the median value of 10 measurements. Liver stiffness and
CAP were obtained simultaneously and in the same volume of liver
parenchyma. CAP was computed only when the associated liver
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stiffness measurement was valid. The ﬁnal CAP value result was
expressed in dB/m and was the median value of 10 measurements.
Hepatic steatosis was graded as mild (steatosis grade 1 or
S1), moderate (steatosis grade 2 or S2), or severe (steatosis grade
3 or S3) based on previous reported cutoff.27 Brieﬂy, mild liver
steatosis (S1) was deﬁned as CAP values between 216 and 252
dB/m; moderate liver steatosis (S2) was deﬁned as CAP values
between 253 and 296 dB/m; severe liver steatosis (S3) was
deﬁned as CAP . 296 dB/m. Hepatic steatosis was deﬁned as
a steatosis grade $S1.
PNPLA3 rs738409 Genotyping
For the Catanzaro cohort, DNA was extracted from saliva by
NucleoSpin technology (Macherey-Nagel GmbH & Co., Düren,
Germany) or from buccal brush by Puregene Buccal Cell Core Kit
(Qiagen, Venlo, the Netherlands), and the rs738409 polymorphism
(encoding for PNPLA3 I148M) determined by 5’-nuclease Taqman
assays (Life Technologies, Carlsbad, CA) as described before.7 For
the Milan cohort, DNA was extracted from peripheral blood samples
by the phenol-chloroform method, and the rs738409 polymorphism
determined using the Taqman assay as described before.28
Statistical Analyses
Genotype and allele frequencies and also categorical
variables’ distribution across genotypes were compared by x2
test or by Fisher’s exact test. In the Catanzaro cohort, the P
values for continuous variables were calculated using linear
regression analysis under an additive model after adjusting for
age, sex, BMI, and mesalamine use when appropriate; the P
values for steatosis presence were calculated by binary logistic
regression analysis under an additive model after adjusting for
age, sex, BMI, and mesalamine use. In the Milan cohort, the P
value for ALT levels was calculated using linear regression
analysis under an additive model after adjusting for age, sex,
and mesalamine use. ALT levels among PNPLA3 I148M geno-
types in subjects with CD and in subjects with UC were ana-
lyzed using linear regression analysis under an additive model
after adjusting for age, sex, and mesalamine use (Catanzaro and
Milan cohorts) or for age, sex, mesalamine use, and recruitment
center (Catanzaro plus Milan cohort). Weighted-mean and
weighted-SD were calculated to show ALT levels in the com-
bined Catanzaro plus Milan cohort.
All statistical analyses were performed using the Statistical
Package for Social Sciences (version 19.0; SPSS, Inc., Chicago,
IL). P values , 0.05 were considered as statistically signiﬁcant.
ETHICAL CONSIDERATIONS
The study was approved by ethics committee of University
Magna Graecia (protocol number 2014/49) and by the Institu-
tional Review Board of the Fondazione IRCCS Ca’ Granda Ospe-
dale Policlinico, Milano. All patients participated in this study in
conﬁrmation with the principles outlined in the Declaration of
Helsinki. Informed written consent was obtained from each par-
ticipating patient.
RESULTS
PNPLA3 148M Carriers with IBD Have Higher
Risk of Hepatic Steatosis and Higher
Circulating ALT in the Catanzaro Cohort
A total of 158 European individuals (mean age 45 6 13 yr)
with IBD from Southern Italy (namely, Catanzaro cohort) were
examined. Characteristics of the Catanzaro cohort are shown in
Table 1. Most individuals from this cohort were normal weight,
approximately one-third had CD, whereas the remaining had UC.
The mean disease duration was of 8 years, and approximately
40% of individuals were in remission. Among individuals with
CD, most had ileal or ileocolonic disease location and 25% under-
went ileocecal resection. Among individuals with UC, most
(60%) had pancolitis disease location. Hepatic steatosis estimated
by elastography (CAP $ 216 db/m) was present in approximately
70% of the individuals.
We found a positive correlation between the presence of
hepatic steatosis assessed by sonography and by elastography (r ¼
0.414 and P , 0.001). ALT levels were progressively higher in
individuals with increasing degree of hepatic fat content measured
by elastography (Fig. 1).
The PNPLA3 I148M genotypes and allele frequencies were
in Hardy–Weinberg equilibrium (P ¼ 0.144) with a minor allele
frequency of 0.24. Carriers of the PNPLA3 148M allele had high-
er CAP values (P ¼ 0.029) after adjusting for age, sex, BMI, and
mesalamine use or after adjusting for age, sex, BMI, and treatment
(P ¼ 0.046) (see Tables, Supplemental Digital Content 1 and 2,
http://links.lww.com/IBD/B85 and http://links.lww.com/IBD/
B86), suggesting a higher content of fat in the liver. P value for
CAP values remained signiﬁcant also after adjusting for age, sex,
BMI, mesalamine use, and disease duration (P ¼ 0.033). Carriers
of the 148M allele have higher prevalence of hepatic steatosis
deﬁned as CAP $ 216 db/m (P ¼ 0.036 after adjusting for age,
sex, BMI, and mesalamine use and P ¼ 0.035 after adjusting also
for disease duration, see Table, Supplemental Digital Content 1,
http://links.lww.com/IBD/B85) and increased risk for this condi-
tion (odds ratio, 2.9, and conﬁdence interval, 1.1–7.8) indepen-
dently from other risk factors. After adjusting for age, sex, BMI,
and treatment, P ¼ 0.061 for hepatic steatosis (see Table, Sup-
plemental Digital Content 3, http://links.lww.com/IBD/B87). In
patients with CD, steatosis presence measured by transient elas-
tography did not correlate with ileocecal resection status (r ¼
20.167 and P ¼ 0.309) or with disease location (r ¼ 0.221 and
P ¼ 0.176). PNPLA3 148M carriers had also higher ALT levels
(P ¼ 0.035, Fig. 2A and see Table, Supplemental Digital Content
1, http://links.lww.com/IBD/B85) after adjusting for age, sex,
BMI, and mesalamine use or after adjusting for age, sex, BMI,
and treatment (P ¼ 0.021, see Table, Supplemental Digital Con-
tent 4, http://links.lww.com/IBD/B88). P value for ALT levels
remained signiﬁcant also after adjusting for age, sex, BMI, mesal-
amine use, and disease duration (P ¼ 0.034). The frequency of
individuals with ALT . 40 U/L was higher in carriers of the M
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allele (P ¼ 0.004). No differences in the disease activity or dis-
ease location were detected across PNPLA3 genotypes.
PNPLA3 148M Carriers with IBD Have Higher
Serum Aminotransferase Activities in the
Milan Cohort
To conﬁrm our data, we examined the differences in ALT
levels among PNPLA3 I148M genotypes in an independent cohort
of individuals with IBD from Milan (Milan cohort, Table 2). In
this cohort, the proportion of subjects with CD was higher and
individuals were older (CD 34% versus 45% and P ¼ 0.025;
mean age 456 13 versus 496 15 yr and P ¼ 0.012, in Catanzaro
TABLE 1. Anthropometric, Clinical, and Biochemical
Characteristics of Individuals with CD or UC from
Catanzaro
Catanzaro Cohort
N 158
Demographic and anthropometric
Male gender, n (%) 97 (62)
BMI, kg/m2 26 6 4
Age, yr 45 6 13
Diabetes, n (%) 13 (8)
ALT, U/L 23 6 19
ALT . 40 U/L, n (%) 13 (8)
Total bilirubin, mg/dL 0.6 6 0.4
Direct bilirubin, mg/dL 0.2 6 0.1
CAP value, dB/m 243 6 49
Liver stiffness value, kPa 5.4 6 1.9
Steatosis presence
Sonography,a n (%) 73 (67)
Transient elastography,b n (%) 75 (71)
Disease characteristics
CD/UC, n (%) 53/105 (34/66)
Disease duration, yr 8 6 7
Remission, n (%) 69 (44)
Disease location, n (% of CD patients)
Ileal 23 (43)
Ileocolonic 22 (42)
Colonic 3 (6)
Upper disease 5 (9)
Ileocecal resection, n (% of CD patients) 14 (26)
Disease location, n (% of UC patients)
Proctitis 10 (10)
Proctosigmoiditis 13 (12)
Left side 15 (14)
Pancolitis 66 (63)
Medication use
Steroids, n (%) 8 (5)
Thiopurine, n (%) 26 (17)
Mesalamine, n (%) 144 (92)
Anti-TNFa, n (%) 26 (17)
PNPLA3 I148M
II (%) 87 (55)
IM (%) 65 (41)
MM (%) 6 (4)
Continuous variables are shown as mean 6 SD. Categorical variables are presented as
number and proportion (%).
aSonography was performed in 109 individuals.
bTransient elastography was performed in 106 individuals. Only values with 10 valid
shots and with interquartile range/median liver stiffness ratio #30% were included in the
analysis according to manufacturer.24
N, number; II, homozygous for the PNPLA3 148I allele; IM, heterozygous; MM,
homozygous for the PNPLA3 148M allele; TNFa, tumor necrosis factor-alpha.
FIGURE 1. ALT levels stratiﬁed by steatosis grade measured by tran-
sient elastography. ALT levels are progressively higher in individuals
with increasing degree of hepatic steatosis assessed by transient
elastography. Hepatic steatosis was graded as absent (S0, CAP # 215
dB/m), mild (S1, CAP values between 216 and 252 dB/m), moderate
(S2, CAP values between 253 and 296 dB/m), or severe (S3, CAP . 296
dB/m). The difference in ALT levels among steatosis grades was
examined using linear regression analysis. Values were log-trans-
formed before entering the model. Data are shown as mean; numbers
in brackets above the bars represent the SDs.
FIGURE 2. ALT levels stratiﬁed by PNPLA3 I148M genotype. In both
Catanzaro (CZ) and Milan (MI) cohorts, ALT levels are higher in
PNPLA3 148M allele carriers with CD or UC. The difference in ALT
levels among PNPLA3 I148M genotypes in the (A) CZ cohort and (B)
MI cohort was examined using linear regression analyses under an
additive model after adjusting for age, sex, BMI, and mesalamine use
(CZ cohort and MI cohort). Values were log-transformed before
entering the model. Data are shown as mean; numbers in brackets
above the bars represent the SDs. N, number of individuals; II, in-
dividuals with two 148I alleles; IM, heterozygotes; MM, individuals
with two 148M alleles.
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and Milan cohort, respectively). The proportion of individuals in
remission was higher (44% versus 56% and P ¼ 0.023). Further-
more, possibly because of the different clinical characteristics,
overall ALT levels were lower in subjects from the Milan cohort
compared with the Catanzaro cohort (146 9 versus 236 19 U/L,
P , 0.001). Among individuals with CD from the Milan cohort,
most had ileal or ileocolonic disease location, whereas among
individuals with UC, most (44%) had proctosigmoiditis.
The PNPLA3 I148M genotypes in the Milan cohort were in
Hardy–Weinberg equilibrium (P ¼ 0.908) with a minor allele fre-
quency of 0.25. Consistent with the ﬁndings in the Catanzaro cohort,
ALT levels were higher in carriers of the 148M allele from the Milan
cohort (P , 0.001) after adjusting for age, sex, and mesalamine use
(Fig. 2B). No differences in the frequency of individuals with ALT
. 40 U/L, in the disease activity or disease location across PNPLA3
genotypes, were detected in the Milan cohort (see Table, Supple-
mental Digital Content 5, http://links.lww.com/IBD/B89).
PNPLA3 148M Carriers with CD and UC Have
Higher Liver Enzymes
To investigate whether the increased ALT levels found in
carriers of the PNPLA3 148M allele were disease speciﬁc, we
examined ALT levels among genotypes separately in individuals
with CD and UC after pooling the Catanzaro and Milan cohorts.
Carriers of the PNPLA3 148M allele had higher ALT levels in
both CD and UC subgroups (P ¼ 0.002 and P , 0.001, respec-
tively) after adjusting for age, sex, mesalamine use, and center of
recruitment (Table 3 and Fig. 3). In a sensitivity analysis, we
examined the impact of PNPLA3 148M on ALT separately in
the 2 cohorts. ALT was higher in PNPLA3 148M carriers with
CD and UC in both cohorts, although statistical signiﬁcance was
observed only in the Milan cohort (P ¼ 0.002 and P ¼ 0.001,
respectively) (Table 3).
DISCUSSION
In this study, we report for the ﬁrst time that PNPLA3
148M carriers with IBD have higher risk of hepatic steatosis
and higher biomarker of liver damage. Speciﬁcally, we showed
increased hepatic steatosis and higher fat content measured by
transient elastography in PNPLA3 148M carriers with IBD from
Southern Italy. We also showed that PNPLA3 148M carriers have
higher hepatic damage measured by ALT levels in 2 independent
cohorts from Italy. Among all medication treatment, mesalamine
use was different across PNPLA3 genotypes. Therefore, at multi-
variate analysis, we adjusted the association of PNPLA3 genotype
with liver damage for this confounder.
Sonography is the most used noninvasive method to assess
the presence of hepatic steatosis. Transient elastography is a method
used to estimate the severity of liver ﬁbrosis and recently hepatic fat
content. We found a strong correlation between hepatic steatosis
assessed by sonography and the CAP evaluated by elastography,
indicating that elastography allows detecting hepatic steatosis. ALT
levels were progressively higher with increasing degree of hepatic
fat content assessed by transient elastography. These data show that
increased hepatic fat content is associated with higher ALT levels
in individuals with IBD. We also found an increased frequency of
individuals with ALT. 40 U/L in carriers of the M allele from the
Catanzaro cohort. We did not detect the same difference in indi-
viduals from the Milan cohort. The lack of association in the Milan
cohort is possibly explained by the lower overall ALT levels and
different clinical proﬁles of this cohort.
IBD encompass CD and UC, 2 distinct diseases with
peculiar features. The association between IBD and increased
hepatic fat has been previously reported.5,6 To test whether the
susceptibility to higher hepatic damage conferred by the PNPLA3
I148M variant was disease speciﬁc, we examined the ALT levels
separately in the 2 diseases. We found carriers of the PNPLA3
148M allele to have higher liver damage in both CD and UC.
TABLE 2. Anthropometric, Clinical, and Biochemical
Characteristics of Individuals with CD or UC from Milan
Milan cohort
N 207
Demographic and anthropometric
Male gender (%) 127 (61)
Age, yr 49 6 15
ALT, U/L 14 6 9
ALT . 40 U/L, n (%) 3 (1)
Disease characteristics
CD/UC, n (%) 94/113 (45/55)
Remission, n (%) 116 (56)
Disease location, n (% of CD patients)
Ileal 36 (38)
Ileocolonic 41 (44)
Colonic 15 (16)
Upper disease 1 (1)
Disease location, n (% of UC patients)
Proctitis 1 (1)
Proctosigmoiditis 50 (44)
Left side 23 (20)
Pancolitis 30 (27)
Medication use
Steroids, n (%) 39 (19)
Thiopurine, n (%) 17 (8)
Mesalamine, n (%) 168 (81)
PNPLA3 I148M
II (%) 115 (56)
IM (%) 79 (38)
MM (%) 13 (6)
Continuous variables are shown as mean 6 SD. Categorical variables are presented as
number and proportion (%).
N, number; II, homozygous for the PNPLA3 148I allele; IM, heterozygous; MM, homo-
zygous for the PNPLA3 148M allele.
Mancina et al Inﬂamm Bowel Dis  Volume 22, Number 1, January 2016
138 | www.ibdjournal.org
These data suggest a common mechanism responsible for the
susceptibility to hepatic steatosis in the 2 diseases.
It has been reported that hepatic steatosis is not related to
IBD site, duration, disease activity, or medical treatment,6
although drug-induced liver damage has been described.4,29,30
Abnormal composition of the gut microbiota and increased
intestinal permeability are a hallmark of IBD.1 Several studies
show a relationship among the gut microbiota, intestinal perme-
ability, and hepatic steatosis and damage.31–33 Inﬂamed gut
mucosa is enriched in bacteria metabolizing lipids.34 PNPLA3
has a triglyceride hydrolase activity,8,9 but the mutant 148M
protein is a loss of function. We, therefore, speculate that differ-
ences in the hepatic fat content may be due to a failure in the
hydrolysis of triglycerides in carriers of the mutant protein.
Additionally, when the bowel integrity is compromised the dis-
ruption of the enterohepatic circulation of bile salts, the altered
composition of the gut microbiota and intestinal immunity may
also be important underlying mechanisms.35 Indeed, increased
intestinal permeability and subsequent exposure of the liver to
cytokines and bacterial products may contribute in the pathogen-
esis of increased liver fat.
PNPLA3 has been studied in hepatocyte19 and hepatic stel-
late cells.7 Genetic studies on primary sclerosing cholangitis and
on primary biliary cirrhosis suggest that this protein may have
a role also in the cholangiocyte.36,37 Indeed, the I148M variant has
been associated with worse prognosis in patients with severe pri-
mary sclerosing cholangitis, a disease of biliary tree strongly
associated with IBD.37 We and others have shown that in a variety
of conditions including obesity,14 viral infections,11,18 and excess
alcohol intake,20 PNPLA3 148M carriers have higher hepatic fat
content and liver damage. Here, we expand the interaction of
PNPLA3 genotype also to the IBD.
In conclusion, our results show that PNPLA3 148M carriers
with IBD have higher susceptibility to hepatic steatosis and liver
damage. Future studies are warranted to understand the molecular
mechanism behind this association.
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FIGURE 3. ALT levels stratiﬁed by PNPLA3 I148M genotype in subjects
with CD or UC from the combined Catanzaro and Milan cohort. ALT
levels are higher in PNPLA3 148M allele carriers with CD or UC. The
difference in ALT levels among PNPLA3 I148M genotypes in individuals
with (A) CD or (B) UC from the combined Catanzaro and Milan cohort
was examined using linear regression analyses under an additive
model after adjusting for age, sex, mesalamine use, and recruitment
center. ALT values were log-transformed before entering the model.
Data are shown as weighted-mean; numbers in brackets above the
bars represent the weighted-SD. N, number of individuals; II, in-
dividuals with two 148I alleles; IM, heterozygotes; MM, individuals with
two 148M alleles.
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